# Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban

> **NCT03809481** · PHASE3 · TERMINATED · sponsor: **Aspen Global Incorporated** · enrollment: 7 (actual)

## Conditions studied

- Heparin-induced Thrombocytopenia

## Interventions

- **DRUG:** Danaparoid Sodium
- **DRUG:** Argatroban

## Key facts

- **NCT ID:** NCT03809481
- **Lead sponsor:** Aspen Global Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-16
- **Primary completion:** 2022-06-10
- **Final completion:** 2022-06-10
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Prolonged delay as a result of impact of Covid19 pandemic
- **Last updated:** 2022-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03809481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03809481, "Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03809481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*